Product Information

RIVASTIGMINE 13.3 MG/24HR PTCH is a generic product labeled by Breckenridge Pharmaceutical Inc., priced at $1.8475 per EA under NDC 51991089930. Its NADAC has been published 355 times since Feb 5, 2020.

FDA first approved this application on Nov 26, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

RIVASTIGMINE 13.3 MG/24HR PTCH

Rivastigmine
$1.8475per EA

Strength

13.3 mg/24h

NDC

51991089930

Classification

Generic

Dosage Form

PATCH, EXTENDED RELEASE

Route

TRANSDERMAL

Effective Date

11/18/2026

Active Ingredients

RIVASTIGMINE

Approval Type

Generic (ANDA)

FDA Application

ANDA209063

FDA Approved

11/26/2019

TE Code

AB

On Market Since

12/19/2019

Pharmacological Classes

Cholinesterase Inhibitor
Cholinesterase Inhibitors

Price Statistics

The NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has been published 355 times since Feb 5, 2020, and over the history we have for it it has declined 56.5%. The table below summarizes its recorded NADAC range and movement.

Current price$1.8475 per EA
All-time high$4.5522 (Apr 15, 2020)
All-time low$1.6436 (Apr 17, 2024)
52-week high$2.0633
52-week low$1.7804
Median price$2.2778
Average price$2.6147
Largest weekly change-33.3% (Apr 17, 2024)
Weeks tracked355
Tracking sinceFeb 5, 2020

Price History

1W

+3.8%

1M

+2.9%

3M

+2.4%

6M

-4.5%

1Y

-4.4%

3Y

-1.6%

5Y

-49.3%

All

-56.5%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of RIVASTIGMINE 13.3 MG/24HR PTCH?

The current National Average Drug Acquisition Cost (NADAC) for RIVASTIGMINE 13.3 MG/24HR PTCH, manufactured by Breckenridge Pharmaceutical Inc., is $1.8475 per EA (NDC 51991089930), effective Nov 18, 2026.

How has the price of RIVASTIGMINE 13.3 MG/24HR PTCH changed over time?

Over the history we have for it, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has declined 56.5%. It has been tracked across 355 weekly CMS publications since Feb 5, 2020.

What are the highest and lowest recorded NADAC prices for RIVASTIGMINE 13.3 MG/24HR PTCH?

Since Feb 5, 2020, the NADAC for RIVASTIGMINE 13.3 MG/24HR PTCH has ranged from a low of $1.6436 (Apr 17, 2024) to a high of $4.5522 (Apr 15, 2020), with a median of $2.2778 per EA.

Are there cheaper alternatives to RIVASTIGMINE 13.3 MG/24HR PTCH?

3 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RIVASTIGMINE 13.3 MG/24HR PTCH in a comparable dosage form, but none are currently priced below it.

Who manufactures RIVASTIGMINE 13.3 MG/24HR PTCH?

RIVASTIGMINE 13.3 MG/24HR PTCH (NDC 51991089930) is labeled by Breckenridge Pharmaceutical Inc., and CMS classifies it as a generic product.